Workflow
ZERO2IPO(01945)
icon
Search documents
清科控股10月13日斥资2016港元回购1600股
Zhi Tong Cai Jing· 2025-10-13 09:52
清科控股(01945)发布公告,该公司于2025年10月13日斥资2016港元回购1600股股份,每股回购价格为 1.25-1.27港元。 ...
清科控股(01945)10月13日斥资2016港元回购1600股
智通财经网· 2025-10-13 09:51
智通财经APP讯,清科控股(01945)发布公告,该公司于2025年10月13日斥资2016港元回购1600股股份, 每股回购价格为1.25-1.27港元。 ...
清科控股(01945) - 翌日披露报表
2025-10-13 09:47
如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 備註: *僅供識別 第 1 頁 共 7 頁 v 1.3.0 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 表格類別: 股票 狀態: 新提交 公司名稱: 清科控股有限公司* 呈交日期: 2025年10月13日 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | ...
清科控股(01945) - 截至二零二五年九月三十日止月份之股份发行人的证券变动月报表
2025-10-08 08:33
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致:香港交易及結算所有限公司 公司名稱: 清科控股有限公司* 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額: USD 50,000 備註: * 僅供 ...
清科控股(01945.HK)9月30日以2636港元回购2000股
Ge Long Hui· 2025-09-30 09:53
格隆汇9月30日丨清科控股(01945.HK)发布公告,2025年9月30日以2,636港元回购2,000股,回购价格每 股1.31-1.34港元。 ...
清科控股(01945)9月30日斥资2636港元回购2000股
智通财经网· 2025-09-30 09:52
智通财经APP讯,清科控股(01945)发布公告,于2025年9月30日斥资2636港元回购2000股股份。 ...
清科控股(01945) - 翌日披露报表
2025-09-30 09:46
表格類別: 股票 狀態: 新提交 公司名稱: 清科控股有限公司* 呈交日期: 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份(不包括庫存股份)數 目 | | 佔有關事件前的現有已發 行股份(不包括庫存股 份)數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註 ...
四位大咖超级对话:创投回暖,AI与创新药的时代才刚开始
创业邦· 2025-09-30 03:49
Core Insights - The Chinese venture capital market is experiencing a revival with a 12% year-on-year increase in fundraising, a 22% increase in investment quantity, and a 38% increase in IPO exits in the first half of 2025, driven by the AI wave and innovative pharmaceuticals [2] - The involvement of state-owned and industrial capital is more pronounced, leading to a shift in narrative and value judgment in the venture capital landscape [3] Group 1: Investment Strategies and Adjustments - Investment frequency has remained stable, with approximately 50 companies invested in annually, while focusing on self-incubation and international expansion [7] - Emphasis on hard technology, AI, advanced manufacturing, new materials, and healthcare, with a focus on maintaining organizational professionalism and market orientation [8] - The strategy has been to continue investing in core technology sectors while adapting to the increasing participation of state-owned and corporate venture capital [9][11] Group 2: Collaboration Over Competition - The current landscape is characterized by collaboration between government funds, corporate venture capital, and market-oriented institutions, rather than competition [11][13] - The government has transitioned from a role focused on attracting investment to becoming a key player in regional industrial development [12][14] - The market is expected to return to a more market-oriented approach in the long term, despite current structural fluctuations [13] Group 3: Future Opportunities in AI and Innovative Pharmaceuticals - The AI sector is seen as a significant opportunity, with investments in AI reaching 750 billion yuan in the first half of 2025, indicating a growing market despite existing gaps compared to the US [17][19] - The narrative around innovative pharmaceuticals is also evolving, with a notable increase in interest from international pharmaceutical companies in Chinese products [17][19] - The focus is on leveraging China's strengths in industrial applications and biomedicine, with a belief that persistence in investment will yield substantial returns in the future [19]
清科控股(01945)9月29日斥资2080港元回购1600股
智通财经网· 2025-09-29 10:00
Core Viewpoint - Qingke Holdings (01945) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 1,600 shares at a total cost of 2,080 HKD [1] - The buyback price per share is set at 1.3 HKD [1] - The buyback is scheduled for September 29, 2025 [1]
清科控股9月29日斥资2080港元回购1600股
Zhi Tong Cai Jing· 2025-09-29 09:58
Core Viewpoint - Qingke Holdings (01945) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company plans to repurchase 1,600 shares at a total cost of 2,080 HKD, translating to a buyback price of 1.3 HKD per share [1]